{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T14:51:54Z","timestamp":1781880714741,"version":"3.54.5"},"reference-count":158,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T00:00:00Z","timestamp":1777680000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"vor","delay-in-days":48,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-026-05125-7","type":"journal-article","created":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T12:03:33Z","timestamp":1777723413000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeting the immunological synapse in multiple myeloma"],"prefix":"10.1007","volume":"17","author":[{"given":"Liu","family":"Sumei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6341-7121","authenticated-orcid":false,"given":"Forouzan","family":"Bahmani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,2]]},"reference":[{"issue":"11","key":"5125_CR1","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1158\/2326-6066.CIR-14-0161","volume":"2","author":"ML Dustin","year":"2014","unstructured":"Dustin ML. The immunological synapse. Cancer Immunol Res. 2014;2(11):1023\u201333.","journal-title":"Cancer Immunol Res"},{"issue":"6697","key":"5125_CR2","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/25764","volume":"395","author":"CR Monks","year":"1998","unstructured":"Monks CR, et al. Three-dimensional segregation of supramolecular activation clusters in T cells. Nature. 1998;395(6697):82\u20136.","journal-title":"Nature"},{"key":"5125_CR3","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1146\/annurev-cellbio-100814-125330","volume":"32","author":"ML Dustin","year":"2016","unstructured":"Dustin ML, Choudhuri K. Signaling and Polarized Communication Across the T Cell Immunological Synapse. Annu Rev Cell Dev Biol. 2016;32:303\u201325.","journal-title":"Annu Rev Cell Dev Biol"},{"issue":"3","key":"5125_CR4","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1083\/jcb.201002027","volume":"189","author":"GM Griffiths","year":"2010","unstructured":"Griffiths GM, Tsun A, Stinchcombe JC. The immunological synapse: a focal point for endocytosis and exocytosis. J Cell Biol. 2010;189(3):399\u2013406.","journal-title":"J Cell Biol"},{"issue":"2","key":"5125_CR5","doi-asserted-by":"publisher","first-page":"327","DOI":"10.3390\/jcm14020327","volume":"14","author":"D Fotiou","year":"2025","unstructured":"Fotiou D, Katodritou E. From biology to clinical practice: the bone marrow microenvironment in multiple myeloma. J Clin Med. 2025;14(2):327.","journal-title":"J Clin Med"},{"issue":"1","key":"5125_CR6","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1186\/s12943-022-01648-z","volume":"21","author":"Y Liang","year":"2022","unstructured":"Liang Y, et al. Malignant clonal evolution drives multiple myeloma cellular ecological diversity and microenvironment reprogramming. Mol Cancer. 2022;21(1):182.","journal-title":"Mol Cancer"},{"issue":"1","key":"5125_CR7","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41572-024-00529-7","volume":"10","author":"F Malard","year":"2024","unstructured":"Malard F, et al. Multiple myeloma. Nat Reviews Disease Primers. 2024;10(1):45.","journal-title":"Nat Reviews Disease Primers"},{"key":"5125_CR8","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3390\/cancers15061682","volume":"15","author":"P Weir","year":"2023","unstructured":"Weir P, et al. Metabolic alterations in multiple myeloma: from oncogenesis to proteasome inhibitor resistance. Cancers (Basel). 2023;15:6.","journal-title":"Cancers (Basel)"},{"issue":"15","key":"5125_CR9","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1182\/blood.2025028896","volume":"146","author":"RKH Yip","year":"2025","unstructured":"Yip RKH, et al. Profiling the spatial architecture of multiple myeloma in human bone marrow trephine biopsy specimens with spatial transcriptomics. Blood. 2025;146(15):1837\u201349.","journal-title":"Blood"},{"key":"5125_CR10","doi-asserted-by":"publisher","first-page":"606368","DOI":"10.3389\/fonc.2020.606368","volume":"10","author":"L Yamamoto","year":"2020","unstructured":"Yamamoto L, et al. Harnessing the Immune System Against Multiple Myeloma: Challenges and Opportunities. Front Oncol. 2020;10:606368.","journal-title":"Front Oncol"},{"issue":"1","key":"5125_CR11","doi-asserted-by":"publisher","first-page":"5011","DOI":"10.1038\/s41467-023-40584-4","volume":"14","author":"L John","year":"2023","unstructured":"John L, et al. Resolving the spatial architecture of myeloma and its microenvironment at the single-cell level. Nat Commun. 2023;14(1):5011.","journal-title":"Nat Commun"},{"issue":"20","key":"5125_CR12","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1182\/blood.2024024590","volume":"144","author":"M John","year":"2024","unstructured":"John M, et al. Spatial transcriptomics reveals profound subclonal heterogeneity and T-cell dysfunction in extramedullary myeloma. Blood. 2024;144(20):2121\u201335.","journal-title":"Blood"},{"key":"5125_CR13","doi-asserted-by":"publisher","first-page":"101189","DOI":"10.1016\/j.neo.2025.101189","volume":"66","author":"M Kamal","year":"2025","unstructured":"Kamal M, et al. Single-cell proteomic analysis reveals Multiple Myeloma heterogeneity and the dynamics of the tumor immune microenvironment in precursor and advanced states. Neoplasia. 2025;66:101189.","journal-title":"Neoplasia"},{"key":"5125_CR14","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3230.BCD-25-0334","author":"IA Roseth","year":"2026","unstructured":"Roseth IA, et al. Multiplexed imaging reveals immune-metabolic niches in multiple myeloma linked to progression and bone disease. Blood Cancer Discov. 2026. https:\/\/doi.org\/10.1158\/2643-3230.BCD-25-0334.","journal-title":"Blood Cancer Discov"},{"key":"5125_CR15","doi-asserted-by":"publisher","first-page":"973836","DOI":"10.3389\/fonc.2022.973836","volume":"12","author":"AG Solimando","year":"2022","unstructured":"Solimando AG, et al. Drug resistance in multiple myeloma: Soldiers and weapons in the bone marrow niche. Front Oncol. 2022;12:973836.","journal-title":"Front Oncol"},{"issue":"2","key":"5125_CR16","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1369\/0022155419896802","volume":"68","author":"DK Walters","year":"2020","unstructured":"Walters DK, Jelinek DF. Multiplex Immunofluorescence of Bone Marrow Core Biopsies: Visualizing the Bone Marrow Immune Contexture. J Histochem Cytochem. 2020;68(2):99\u2013112.","journal-title":"J Histochem Cytochem"},{"issue":"5","key":"5125_CR17","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s43018-020-0053-3","volume":"1","author":"O Zavidij","year":"2020","unstructured":"Zavidij O, et al. Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma. Nat Cancer. 2020;1(5):493\u2013506.","journal-title":"Nat Cancer"},{"issue":"1","key":"5125_CR18","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1038\/s41420-023-01765-8","volume":"9","author":"H Chen","year":"2023","unstructured":"Chen H, et al. What happens to regulatory T cells in multiple myeloma. Cell Death Discov. 2023;9(1):468.","journal-title":"Cell Death Discov"},{"issue":"5","key":"5125_CR19","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.blre.2016.04.002","volume":"30","author":"E Malek","year":"2016","unstructured":"Malek E, et al. Myeloid-derived suppressor cells: The green light for myeloma immune escape. Blood Rev. 2016;30(5):341\u20138.","journal-title":"Blood Rev"},{"issue":"4","key":"5125_CR20","doi-asserted-by":"publisher","first-page":"924","DOI":"10.3390\/cancers12040924","volume":"12","author":"H Tamura","year":"2020","unstructured":"Tamura H, et al. PD-L1-PD-1 pathway in the pathophysiology of multiple myeloma. Cancers (Basel). 2020;12(4):924.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"5125_CR21","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s13045-016-0345-3","volume":"9","author":"C Zelle-Rieser","year":"2016","unstructured":"Zelle-Rieser C, et al. T cells in multiple myeloma display features of exhaustion and senescence at the tumor site. J Hematol Oncol. 2016;9(1):116.","journal-title":"J Hematol Oncol"},{"issue":"12","key":"5125_CR22","first-page":"1","volume":"85","author":"XH Gao","year":"2024","unstructured":"Gao XH, et al. A Retrospective Analysis of Morbidity and Risk Factors of Multiple Myeloma with Peripheral Neuropathy. Br J Hosp Med (Lond). 2024;85(12):1\u201310.","journal-title":"Br J Hosp Med (Lond)"},{"key":"5125_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13020217","author":"A Garc\u00eda-Ortiz","year":"2021","unstructured":"Garc\u00eda-Ortiz A, et al. The role of tumor microenvironment in multiple myeloma development and progression. Cancers. 2021. https:\/\/doi.org\/10.3390\/cancers13020217.","journal-title":"Cancers"},{"issue":"11","key":"5125_CR24","doi-asserted-by":"publisher","first-page":"4351","DOI":"10.1007\/s00277-024-05843-4","volume":"103","author":"HY Xue","year":"2024","unstructured":"Xue HY, Wei F. TGF-\u03b2: an active participant in the immune and metabolic microenvironment of multiple myeloma: TGF-\u03b2 in the microenvironment of multiple myeloma. Ann Hematol. 2024;103(11):4351\u201362.","journal-title":"Ann Hematol"},{"key":"5125_CR25","doi-asserted-by":"publisher","first-page":"p293479","DOI":"10.1155\/2012\/293479","volume":"2012","author":"WM Braga","year":"2012","unstructured":"Braga WM, Atanackovic D, Colleoni GW. The role of regulatory T cells and TH17 cells in multiple myeloma. Clin Dev Immunol. 2012;2012:p293479.","journal-title":"Clin Dev Immunol"},{"key":"5125_CR26","doi-asserted-by":"publisher","first-page":"1102471","DOI":"10.3389\/fimmu.2022.1102471","volume":"13","author":"C Giannotta","year":"2023","unstructured":"Giannotta C, Autino F, Massaia M. The immune suppressive tumor microenvironment in multiple myeloma: The contribution of myeloid-derived suppressor cells. Front Immunol. 2023;13:1102471.","journal-title":"Front Immunol"},{"issue":"26","key":"5125_CR27","doi-asserted-by":"publisher","first-page":"5385","DOI":"10.1182\/blood-2009-10-246660","volume":"115","author":"RH Prabhala","year":"2010","unstructured":"Prabhala RH, et al. Elevated IL-17 produced by Th17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma. Blood. 2010;115(26):5385\u201392.","journal-title":"Blood"},{"issue":"1","key":"5125_CR28","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s40164-022-00267-0","volume":"11","author":"Y Zhao","year":"2022","unstructured":"Zhao Y, et al. Increased TOX expression associates with exhausted T cells in patients with multiple myeloma. Experimental Hematol Oncol. 2022;11(1):12.","journal-title":"Experimental Hematol Oncol"},{"key":"5125_CR29","doi-asserted-by":"publisher","first-page":"949","DOI":"10.3389\/fimmu.2019.00949","volume":"10","author":"FM Consonni","year":"2019","unstructured":"Consonni FM, et al. Myeloid-derived suppressor cells: ductile targets in disease. Front Immunol. 2019;10:949.","journal-title":"Front Immunol"},{"issue":"16","key":"5125_CR30","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1182\/blood.2023022000","volume":"143","author":"S Takahashi","year":"2024","unstructured":"Takahashi S, et al. Regulatory T cells suppress myeloma-specific immunity during autologous stem cell mobilization and transplantation. Blood. 2024;143(16):1656\u201369.","journal-title":"Blood"},{"key":"5125_CR31","doi-asserted-by":"publisher","first-page":"613007","DOI":"10.3389\/fimmu.2020.613007","volume":"11","author":"F Costa","year":"2021","unstructured":"Costa F, et al. PD-L1\/PD-1 pattern of expression within the bone marrow immune microenvironment in smoldering myeloma and active multiple myeloma patients. Front Immunol. 2021;11:613007.","journal-title":"Front Immunol"},{"issue":"1","key":"5125_CR32","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s13045-023-01499-1","volume":"16","author":"L Cai","year":"2023","unstructured":"Cai L, et al. Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy. J Hematol Oncol. 2023;16(1):101.","journal-title":"J Hematol Oncol"},{"key":"5125_CR33","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1038\/s43018-024-00818-w","volume":"5","author":"S Richard","year":"2024","unstructured":"Richard S, et al. Clinical response and pathway-specific correlates following TIGIT\u2013LAG3 blockade in myeloma: the MyCheckpoint randomized clinical trial. Nat Cancer. 2024;5:1459\u201364.","journal-title":"Nat Cancer"},{"issue":"8","key":"5125_CR34","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1016\/j.ymthe.2017.06.003","volume":"25","author":"M Mukherjee","year":"2017","unstructured":"Mukherjee M, et al. Quantitative Imaging Approaches to Study the CAR Immunological Synapse. Mol Ther. 2017;25(8):1757\u201368.","journal-title":"Mol Ther"},{"issue":"22","key":"5125_CR35","doi-asserted-by":"publisher","first-page":"4493","DOI":"10.1182\/blood-2012-05-429415","volume":"121","author":"M Witzens-Harig","year":"2013","unstructured":"Witzens-Harig M, et al. Tumor cells in multiple myeloma patients inhibit myeloma-reactive T cells through carcinoembryonic antigen-related cell adhesion molecule-6. Blood. 2013;121(22):4493\u2013503.","journal-title":"Blood"},{"issue":"7","key":"5125_CR36","first-page":"2131","volume":"109","author":"M Casey","year":"2024","unstructured":"Casey M, et al. Harnessing the cytotoxic granule exocytosis to augment the efficacy of T-cell-engaging bispecific antibody therapy. Haematologica. 2024;109(7):2131\u201343.","journal-title":"Haematologica"},{"issue":"1","key":"5125_CR37","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s40164-025-00643-6","volume":"14","author":"Y Hu","year":"2025","unstructured":"Hu Y, et al. Mechanisms of resistance to CAR-T cell therapy in multiple myeloma: latest updates from the 2024 ASH annual meeting. Exp Hematol Oncol. 2025;14(1):45.","journal-title":"Exp Hematol Oncol"},{"key":"5125_CR38","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s41073-019-0064-8","volume":"4","author":"C Baethge","year":"2019","unstructured":"Baethge C, Goldbeck-Wood S, Mertens S. SANRA-a scale for the quality assessment of narrative review articles. Res Integr Peer Rev. 2019;4:5.","journal-title":"Res Integr Peer Rev"},{"issue":"8","key":"5125_CR39","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1542\/hpeds.2022-006690","volume":"12","author":"SS Wallace","year":"2022","unstructured":"Wallace SS, et al. Hierarchy of Evidence Within the Medical Literature. Hosp Pediatr. 2022;12(8):745\u201350.","journal-title":"Hosp Pediatr"},{"issue":"5425","key":"5125_CR40","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1126\/science.285.5425.221","volume":"285","author":"A Grakoui","year":"1999","unstructured":"Grakoui A, et al. The immunological synapse: a molecular machine controlling T cell activation. Science. 1999;285(5425):221\u20137.","journal-title":"Science"},{"issue":"3","key":"5125_CR41","doi-asserted-by":"publisher","first-page":"333","DOI":"10.4049\/jimmunol.2300141","volume":"211","author":"MA Faust","year":"2023","unstructured":"Faust MA, et al. What\u2019s the Catch? The Significance of Catch Bonds in T Cell Activation. J Immunol. 2023;211(3):333\u201342.","journal-title":"J Immunol"},{"issue":"2","key":"5125_CR42","doi-asserted-by":"publisher","first-page":"e20201966","DOI":"10.1084\/jem.20201966","volume":"219","author":"M Shakiba","year":"2021","unstructured":"Shakiba M, et al. TCR signal strength defines distinct mechanisms of T cell dysfunction and cancer evasion. J Exp Med. 2021;219(2):e20201966.","journal-title":"J Exp Med"},{"issue":"1","key":"5125_CR43","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.immuni.2006.04.010","volume":"25","author":"R Varma","year":"2006","unstructured":"Varma R, et al. T cell receptor-proximal signals are sustained in peripheral microclusters and terminated in the central supramolecular activation cluster. Immunity. 2006;25(1):117\u201327.","journal-title":"Immunity"},{"issue":"625","key":"5125_CR44","doi-asserted-by":"publisher","first-page":"eaay8248","DOI":"10.1126\/scisignal.aay8248","volume":"13","author":"BI Philipson","year":"2020","unstructured":"Philipson BI, et al. 4-1BB costimulation promotes CAR T cell survival through noncanonical NF-\u03baB signaling. Sci Signal. 2020;13(625):eaay8248.","journal-title":"Sci Signal"},{"key":"5125_CR45","doi-asserted-by":"publisher","first-page":"1503018","DOI":"10.3389\/fimmu.2024.1503018","volume":"15","author":"K Raychaudhuri","year":"2024","unstructured":"Raychaudhuri K, et al. CD28 shapes T cell receptor signaling by regulating Lck dynamics and ZAP70 activation. Front Immunol. 2024;15:1503018.","journal-title":"Front Immunol"},{"issue":"5","key":"5125_CR46","doi-asserted-by":"publisher","first-page":"e102783","DOI":"10.15252\/embj.2019102783","volume":"39","author":"S Kumari","year":"2020","unstructured":"Kumari S, et al. Cytoskeletal tension actively sustains the migratory T-cell synaptic contact. Embo j. 2020;39(5):e102783.","journal-title":"Embo j"},{"issue":"8","key":"5125_CR47","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.3390\/cells12081136","volume":"12","author":"H Shi","year":"2023","unstructured":"Shi H, Shao B. LFA-1 Activation in T-cell migration and immunological synapse formation. Cells. 2023;12(8):1136.","journal-title":"Cells"},{"issue":"2","key":"5125_CR48","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1083\/jcb.200503032","volume":"170","author":"J Lin","year":"2005","unstructured":"Lin J, Miller MJ, Shaw AS. The c-SMAC: sorting it all out (or in). J Cell Biol. 2005;170(2):177\u201382.","journal-title":"J Cell Biol"},{"issue":"734","key":"5125_CR49","doi-asserted-by":"publisher","first-page":"eadg7962","DOI":"10.1126\/scitranslmed.adg7962","volume":"16","author":"L D\u00edez-Alonso","year":"2024","unstructured":"D\u00edez-Alonso L, et al. Engineered T cells secreting anti-BCMA T cell engagers control multiple myeloma and promote immune memory in vivo. Sci Transl Med. 2024;16(734):eadg7962.","journal-title":"Sci Transl Med"},{"key":"5125_CR50","doi-asserted-by":"publisher","first-page":"e83659","DOI":"10.7554\/eLife.83659","volume":"12","author":"C Liu","year":"2023","unstructured":"Liu C, et al. Population dynamics of immunological synapse formation induced by bispecific T cell engagers predict clinical pharmacodynamics and treatment resistance. eLife. 2023;12:e83659.","journal-title":"eLife"},{"issue":"7","key":"5125_CR51","doi-asserted-by":"publisher","first-page":"115973","DOI":"10.1016\/j.celrep.2025.115973","volume":"44","author":"MS Cook","year":"2025","unstructured":"Cook MS, et al. CAR-T cells containing CD28 versus 4-1BB co-stimulatory domains show distinct metabolic profiles in patients. Cell Rep. 2025;44(7):115973.","journal-title":"Cell Rep"},{"issue":"1","key":"5125_CR52","doi-asserted-by":"publisher","first-page":"e96976","DOI":"10.1172\/jci.insight.96976","volume":"3","author":"S Guedan","year":"2018","unstructured":"Guedan S, et al. Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation. JCI Insight. 2018;3(1):e96976.","journal-title":"JCI Insight"},{"issue":"15","key":"5125_CR53","doi-asserted-by":"publisher","first-page":"3796","DOI":"10.3390\/cancers14153796","volume":"14","author":"R Herv\u00e1s-Salcedo","year":"2022","unstructured":"Herv\u00e1s-Salcedo R, Mart\u00edn-Antonio B. A Journey through the Inter-Cellular Interactions in the Bone Marrow in Multiple Myeloma: Implications for the Next Generation of Treatments. Cancers. 2022;14(15):3796.","journal-title":"Cancers"},{"issue":"1","key":"5125_CR54","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s41232-020-00113-y","volume":"40","author":"N Hosen","year":"2020","unstructured":"Hosen N. Integrins in multiple myeloma. Inflamm Regeneration. 2020;40(1):4.","journal-title":"Inflamm Regeneration"},{"issue":"5","key":"5125_CR55","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1158\/2326-6066.CIR-22-0761","volume":"11","author":"ZLZ Hay","year":"2023","unstructured":"Hay ZLZ, et al. Low TCR Binding Strength Results in Increased Progenitor-like CD8\u2009+\u2009Tumor-Infiltrating Lymphocytes. Cancer Immunol Res. 2023;11(5):570\u201382.","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"5125_CR56","doi-asserted-by":"publisher","first-page":"iqad006","DOI":"10.1093\/oxfimm\/iqad006","volume":"4","author":"E Jenkins","year":"2023","unstructured":"Jenkins E, et al. The current state and future of T-cell exhaustion research. Oxf Open Immunol. 2023;4(1):iqad006.","journal-title":"Oxf Open Immunol"},{"issue":"4","key":"5125_CR57","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/j.ymthe.2018.01.020","volume":"26","author":"W Xiong","year":"2018","unstructured":"Xiong W, et al. Immunological Synapse Predicts Effectiveness of Chimeric Antigen Receptor Cells. Mol Ther. 2018;26(4):963\u201375.","journal-title":"Mol Ther"},{"issue":"8","key":"5125_CR58","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/ni1369","volume":"7","author":"SJ Davis","year":"2006","unstructured":"Davis SJ, van der Merwe PA. The kinetic-segregation model: TCR triggering and beyond. Nat Immunol. 2006;7(8):803\u20139.","journal-title":"Nat Immunol"},{"issue":"8","key":"5125_CR59","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1084\/jem.20151088","volume":"213","author":"A Hashimoto-Tane","year":"2016","unstructured":"Hashimoto-Tane A, et al. Micro\u2013adhesion rings surrounding TCR microclusters are essential for T cell activation. J Exp Med. 2016;213(8):1609\u201325.","journal-title":"J Exp Med"},{"issue":"1","key":"5125_CR60","doi-asserted-by":"publisher","first-page":"4638","DOI":"10.1038\/s41467-025-59818-8","volume":"16","author":"T Kimman","year":"2025","unstructured":"Kimman T, et al. Engineering anti-BCMA CAR T cells for enhancing myeloma killing efficacy via apoptosis regulation. Nat Commun. 2025;16(1):4638.","journal-title":"Nat Commun"},{"issue":"3","key":"5125_CR61","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/icb.2014.93","volume":"93","author":"AM Huehls","year":"2015","unstructured":"Huehls AM, Coupet TA, Sentman CL. Bispecific T-cell engagers for cancer immunotherapy. Immunol Cell Biol. 2015;93(3):290\u20136.","journal-title":"Immunol Cell Biol"},{"issue":"17","key":"5125_CR62","doi-asserted-by":"publisher","first-page":"4180","DOI":"10.1182\/bloodadvances.2020002565","volume":"4","author":"RL Goldstein","year":"2020","unstructured":"Goldstein RL, et al. AMG 701 induces cytotoxicity of multiple myeloma cells and depletes plasma cells in cynomolgus monkeys. Blood Adv. 2020;4(17):4180\u201394.","journal-title":"Blood Adv"},{"issue":"9","key":"5125_CR63","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1111\/jcpt.13741","volume":"47","author":"P Mocquot","year":"2022","unstructured":"Mocquot P, et al. The pharmacology of blinatumomab: state of the art on pharmacodynamics, pharmacokinetics, adverse drug reactions and evaluation in clinical trials. J Clin Pharm Ther. 2022;47(9):1337\u201351.","journal-title":"J Clin Pharm Ther"},{"issue":"8","key":"5125_CR64","doi-asserted-by":"publisher","first-page":"e374","DOI":"10.1016\/S1470-2045(24)00094-9","volume":"25","author":"Y Lin","year":"2024","unstructured":"Lin Y, et al. Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee. Lancet Oncol. 2024;25(8):e374\u201387.","journal-title":"Lancet Oncol"},{"issue":"15","key":"5125_CR65","doi-asserted-by":"publisher","first-page":"3859","DOI":"10.1182\/bloodadvances.2023012470","volume":"8","author":"M Mejia Saldarriaga","year":"2024","unstructured":"Mejia Saldarriaga M, et al. Absolute lymphocyte count after BCMA CAR-T therapy is a predictor of response and outcomes in relapsed multiple myeloma. Blood Adv. 2024;8(15):3859\u201369.","journal-title":"Blood Adv"},{"key":"5125_CR66","doi-asserted-by":"publisher","first-page":"1424925","DOI":"10.3389\/fimmu.2024.1424925","volume":"15","author":"M Rees","year":"2024","unstructured":"Rees M, et al. Bispecific antibody targets and therapies in multiple myeloma. Front Immunol. 2024;15:1424925.","journal-title":"Front Immunol"},{"issue":"1","key":"5125_CR67","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1038\/s41408-024-01191-8","volume":"14","author":"D Swan","year":"2024","unstructured":"Swan D, Madduri D, Hocking J. CAR-T cell therapy in Multiple Myeloma: current status and future challenges. Blood Cancer J. 2024;14(1):206.","journal-title":"Blood Cancer J"},{"issue":"9","key":"5125_CR68","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1038\/s41591-023-02491-5","volume":"29","author":"H Lee","year":"2023","unstructured":"Lee H, et al. Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma. Nat Med. 2023;29(9):2295\u2013306.","journal-title":"Nat Med"},{"issue":"14","key":"5125_CR69","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.3390\/cells14141077","volume":"14","author":"B Tedder","year":"2025","unstructured":"Tedder B, Bhutani M. Resistance mechanisms to BCMA targeting bispecific antibodies and CAR T-cell therapies in multiple myeloma. Cells. 2025;14(14):1077.","journal-title":"Cells"},{"issue":"1","key":"5125_CR70","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s13045-023-01482-w","volume":"16","author":"A Tapia-Galisteo","year":"2023","unstructured":"Tapia-Galisteo A, \u00c1lvarez-Vallina L, Sanz L. Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies. J Hematol Oncol. 2023;16(1):83.","journal-title":"J Hematol Oncol"},{"issue":"2","key":"5125_CR71","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1073\/pnas.90.2.720","volume":"90","author":"Z Eshhar","year":"1993","unstructured":"Eshhar Z, et al. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci U S A. 1993;90(2):720\u20134.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"5125_CR72","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1158\/2159-8290.CD-12-0548","volume":"3","author":"M Sadelain","year":"2013","unstructured":"Sadelain M, Brentjens R, Rivi\u00e8re I. The Basic Principles of Chimeric Antigen Receptor Design. Cancer Discov. 2013;3(4):388\u201398.","journal-title":"Cancer Discov"},{"issue":"9","key":"5125_CR73","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1089\/hum.2014.2532","volume":"25","author":"Z Eshhar","year":"2014","unstructured":"Eshhar Z. From the mouse cage to human therapy: a personal perspective of the emergence of T-bodies\/chimeric antigen receptor T cells. Hum Gene Ther. 2014;25(9):773\u20138.","journal-title":"Hum Gene Ther"},{"issue":"5","key":"5125_CR74","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1016\/j.ymthe.2017.03.034","volume":"25","author":"I Rivi\u00e8re","year":"2017","unstructured":"Rivi\u00e8re I, Sadelain M. Chimeric Antigen Receptors: A Cell and Gene Therapy Perspective. Mol Ther. 2017;25(5):1117\u201324.","journal-title":"Mol Ther"},{"issue":"1","key":"5125_CR75","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s40364-017-0102-y","volume":"5","author":"C Zhang","year":"2017","unstructured":"Zhang C, et al. Engineering CAR-T cells. Biomark Res. 2017;5(1):22.","journal-title":"Biomark Res"},{"issue":"15","key":"5125_CR76","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1016\/j.bpj.2023.09.004","volume":"123","author":"Y Xiong","year":"2024","unstructured":"Xiong Y, Libby KA, Su X. The physical landscape of CAR-T synapse. Biophys J. 2024;123(15):2199\u2013210.","journal-title":"Biophys J"},{"issue":"9","key":"5125_CR77","doi-asserted-by":"publisher","first-page":"E2068","DOI":"10.1073\/pnas.1716266115","volume":"115","author":"AJ Davenport","year":"2018","unstructured":"Davenport AJ, et al. Chimeric antigen receptor T cells form nonclassical and potent immune synapses driving rapid cytotoxicity. Proc Natl Acad Sci. 2018;115(9):E2068\u201376.","journal-title":"Proc Natl Acad Sci"},{"issue":"3","key":"5125_CR78","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1016\/j.ymthe.2021.01.025","volume":"29","author":"W Xiong","year":"2021","unstructured":"Xiong W, et al. Immunological Synapse Predicts Effectiveness of Chimeric Antigen Receptor Cells. Mol Ther. 2021;29(3):1349\u201351.","journal-title":"Mol Ther"},{"issue":"2","key":"5125_CR79","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1182\/bloodadvances.2023011992","volume":"8","author":"C Baguet","year":"2024","unstructured":"Baguet C, Larghero J, Mebarki M. Early predictive factors of failure in autologous CAR T-cell manufacturing and\/or efficacy in hematologic malignancies. Blood Adv. 2024;8(2):337\u201342.","journal-title":"Blood Adv"},{"issue":"2","key":"5125_CR80","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1038\/s41375-023-02129-y","volume":"38","author":"L Fischer","year":"2024","unstructured":"Fischer L, et al. Cellular dynamics following CAR T cell therapy are associated with response and toxicity in relapsed\/refractory myeloma. Leukemia. 2024;38(2):372\u201382.","journal-title":"Leukemia"},{"issue":"12","key":"5125_CR81","doi-asserted-by":"publisher","first-page":"3081","DOI":"10.3390\/cancers15123081","volume":"15","author":"M Mez\u0151si-Csapl\u00e1r","year":"2023","unstructured":"Mez\u0151si-Csapl\u00e1r M, Sz\u00f6\u0151r \u00c1, Vereb G. CD28 and 41BB costimulatory domains alone or in combination differentially influence cell surface dynamics and organization of chimeric antigen receptors and early activation of CAR T Cells. Cancers. 2023;15(12):3081.","journal-title":"Cancers"},{"issue":"10","key":"5125_CR82","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1016\/j.cell.2022.03.041","volume":"185","author":"L Labanieh","year":"2022","unstructured":"Labanieh L, et al. Enhanced safety and efficacy of protease-regulated CAR-T cell receptors. Cell. 2022;185(10):1745\u2013e176322.","journal-title":"Cell"},{"key":"5125_CR83","doi-asserted-by":"publisher","first-page":"665519","DOI":"10.3389\/fcell.2021.665519","volume":"9","author":"L Dupr\u00e9","year":"2021","unstructured":"Dupr\u00e9 L, Boztug K, Pfajfer L. Actin Dynamics at the T Cell Synapse as Revealed by Immune-Related Actinopathies. Front Cell Dev Biol. 2021;9:665519.","journal-title":"Front Cell Dev Biol"},{"issue":"11","key":"5125_CR84","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1038\/ni.2120","volume":"12","author":"KF Kong","year":"2011","unstructured":"Kong KF, et al. A motif in the V3 domain of the kinase PKC-\u03b8 determines its localization in the immunological synapse and functions in T cells via association with CD28. Nat Immunol. 2011;12(11):1105\u201312.","journal-title":"Nat Immunol"},{"key":"5125_CR85","doi-asserted-by":"publisher","first-page":"530","DOI":"10.3389\/fimmu.2015.00530","volume":"6","author":"V Brezar","year":"2015","unstructured":"Brezar V, Tu WJ, Seddiki N. PKC-theta in regulatory and effector T-cell functions. Front Immunol. 2015;6:530.","journal-title":"Front Immunol"},{"key":"5125_CR86","doi-asserted-by":"publisher","first-page":"115135","DOI":"10.1016\/j.addr.2023.115135","volume":"203","author":"L Liu","year":"2023","unstructured":"Liu L, et al. Cellular and molecular imaging of CAR-T cell-based immunotherapy. Adv Drug Deliv Rev. 2023;203:115135.","journal-title":"Adv Drug Deliv Rev"},{"issue":"4","key":"5125_CR87","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1038\/mt.2013.17","volume":"21","author":"CH Lamers","year":"2013","unstructured":"Lamers CH, et al. Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity. Mol Ther. 2013;21(4):904\u201312.","journal-title":"Mol Ther"},{"issue":"1","key":"5125_CR88","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s12943-024-01952-w","volume":"23","author":"Y Wang","year":"2024","unstructured":"Wang Y, et al. Affinity fine-tuning anti-CAIX CAR-T cells mitigate on-target off-tumor side effects. Mol Cancer. 2024;23(1):56.","journal-title":"Mol Cancer"},{"key":"5125_CR89","doi-asserted-by":"publisher","first-page":"1177670","DOI":"10.3389\/fimmu.2023.1177670","volume":"14","author":"HF Chang","year":"2023","unstructured":"Chang HF, et al. Lytic granule exocytosis at immune synapses: lessons from neuronal synapses. Front Immunol. 2023;14:1177670.","journal-title":"Front Immunol"},{"key":"5125_CR90","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.semcdb.2017.07.033","volume":"72","author":"BA Spicer","year":"2017","unstructured":"Spicer BA, et al. Perforin\u2014A key (shaped) weapon in the immunological arsenal. Semin Cell Dev Biol. 2017;72:117\u201323.","journal-title":"Semin Cell Dev Biol"},{"key":"5125_CR91","doi-asserted-by":"publisher","first-page":"1392535","DOI":"10.3389\/fimmu.2024.1392535","volume":"15","author":"R Thompson","year":"2024","unstructured":"Thompson R, Cao X. Reassessing granzyme B: unveiling perforin-independent versatility in immune responses and therapeutic potentials. Front Immunol. 2024;15:1392535.","journal-title":"Front Immunol"},{"issue":"11","key":"5125_CR92","doi-asserted-by":"publisher","first-page":"2952","DOI":"10.1182\/bloodadvances.2023012354","volume":"8","author":"E Letouz\u00e9","year":"2024","unstructured":"Letouz\u00e9 E, et al. Mechanisms of resistance to bispecific T-cell engagers in multiple myeloma and their clinical implications. Blood Adv. 2024;8(11):2952\u20139.","journal-title":"Blood Adv"},{"issue":"8","key":"5125_CR93","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi NC, et al. Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. N Engl J Med. 2021;384(8):705\u201316.","journal-title":"N Engl J Med"},{"key":"5125_CR94","doi-asserted-by":"publisher","first-page":"1613265","DOI":"10.3389\/fimmu.2025.1613265","volume":"16","author":"NT Iannozzi","year":"2025","unstructured":"Iannozzi NT, Giuliani N, Storti P. Deciphering the bone marrow microenvironment\u2019s role in multiple myeloma immunotherapy resistance. Front Immunol. 2025;16:1613265.","journal-title":"Front Immunol"},{"issue":"1","key":"5125_CR95","doi-asserted-by":"publisher","first-page":"e2025045","DOI":"10.4084\/MJHID.2025.045","volume":"17","author":"M Puppi","year":"2025","unstructured":"Puppi M, et al. Bispecific Antibodies and CAR T in Multiple Myeloma: Appropriate Selection of Patients and Sequencing. Mediterr J Hematol Infect Dis. 2025;17(1):e2025045.","journal-title":"Mediterr J Hematol Infect Dis"},{"issue":"1","key":"5125_CR96","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/s41408-024-01139-y","volume":"14","author":"AJ Devasia","year":"2024","unstructured":"Devasia AJ, Chari A, Lancman G. Bispecific antibodies in the treatment of multiple myeloma. Blood Cancer J. 2024;14(1):158.","journal-title":"Blood Cancer J"},{"key":"5125_CR97","doi-asserted-by":"crossref","unstructured":"Lieberman MM, et al. Endogenous CD28 drives CAR T cell responses in multiple myeloma. bioRxiv. 2024.","DOI":"10.1101\/2024.03.21.586084"},{"issue":"4","key":"5125_CR98","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1182\/blood.2023023557","volume":"144","author":"RS Firestone","year":"2024","unstructured":"Firestone RS, et al. Antigen escape as a shared mechanism of resistance to BCMA-directed therapies in multiple myeloma. Blood. 2024;144(4):402\u20137.","journal-title":"Blood"},{"key":"5125_CR99","doi-asserted-by":"publisher","first-page":"1034257","DOI":"10.3389\/fcell.2022.1034257","volume":"10","author":"X Zhu","year":"2022","unstructured":"Zhu X, Li Q, Zhu X. Mechanisms of CAR T cell exhaustion and current counteraction strategies. Front Cell Dev Biol. 2022;10:1034257.","journal-title":"Front Cell Dev Biol"},{"issue":"Supplement 1","key":"5125_CR100","doi-asserted-by":"publisher","first-page":"3356","DOI":"10.1182\/blood-2024-199423","volume":"144","author":"G An","year":"2024","unstructured":"An G, et al. MBS314, a G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) x B-Cell Maturation Antigen (BCMA) x CD3 Trispecific Antibody, in Relapsed and\/or Refractory Multiple Myeloma (RRMM): Preliminary Results from a Phase \u2160, First-in-Human, Open-Label, Dose Escalation Study. Blood. 2024;144(Supplement 1):3356\u20133356.","journal-title":"Blood"},{"issue":"3","key":"5125_CR101","doi-asserted-by":"publisher","first-page":"143","DOI":"10.2217\/imt-2023-0256","volume":"16","author":"L Chen","year":"2024","unstructured":"Chen L, et al. A Trispecific Antibody Induces Potent Tumor-Directed T-Cell Activation and Antitumor Activity by CD3\/CD28 Co-Engagement. Immunotherapy. 2024;16(3):143\u201359.","journal-title":"Immunotherapy"},{"issue":"10","key":"5125_CR102","doi-asserted-by":"publisher","first-page":"879","DOI":"10.3390\/cells13100879","volume":"13","author":"AL Grab","year":"2024","unstructured":"Grab AL, et al. Pre-clinical assessment of SAR442257, a CD38\/CD3xCD28 Trispecific T cell engager in treatment of relapsed\/refractory multiple myeloma. Cells. 2024;13(10):879.","journal-title":"Cells"},{"issue":"3","key":"5125_CR103","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1158\/2767-9764.CRC-23-0434","volume":"4","author":"AL Keller","year":"2024","unstructured":"Keller AL, et al. Ex Vivo Efficacy of SAR442257 Anti-CD38 Trispecific T-cell Engager in Multiple Myeloma Relapsed After Daratumumab and BCMA-targeted Therapies. Cancer Res Commun. 2024;4(3):757\u201364.","journal-title":"Cancer Res Commun"},{"issue":"1","key":"5125_CR104","doi-asserted-by":"publisher","first-page":"3719","DOI":"10.1038\/s41467-023-39265-z","volume":"14","author":"W Promsote","year":"2023","unstructured":"Promsote W, et al. Trispecific antibody targeting HIV-1 and T cells activates and eliminates latently-infected cells in HIV\/SHIV infections. Nat Commun. 2023;14(1):3719.","journal-title":"Nat Commun"},{"issue":"3","key":"5125_CR105","doi-asserted-by":"publisher","first-page":"e010140","DOI":"10.1136\/jitc-2024-010140","volume":"13","author":"Y Sun","year":"2025","unstructured":"Sun Y, et al. Leveraging T cell co-stimulation for enhanced therapeutic efficacy of trispecific antibodies targeting prostate cancer. J Immunother Cancer. 2025;13(3):e010140.","journal-title":"J Immunother Cancer"},{"key":"5125_CR106","doi-asserted-by":"publisher","first-page":"832645","DOI":"10.3389\/fimmu.2022.832645","volume":"13","author":"LM Alabanza","year":"2022","unstructured":"Alabanza LM, et al. Armored BCMA CAR T cells eliminate multiple myeloma and are resistant to the suppressive effects of TGF-\u03b2. Front Immunol. 2022;13:832645.","journal-title":"Front Immunol"},{"issue":"591","key":"5125_CR107","doi-asserted-by":"publisher","first-page":"eabe7378","DOI":"10.1126\/scitranslmed.abe7378","volume":"13","author":"JH Choe","year":"2021","unstructured":"Choe JH, et al. SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma. Sci Transl Med. 2021;13(591):eabe7378.","journal-title":"Sci Transl Med"},{"key":"5125_CR108","doi-asserted-by":"publisher","first-page":"609421","DOI":"10.3389\/fimmu.2021.609421","volume":"12","author":"D Duan","year":"2021","unstructured":"Duan D, et al. The BCMA-targeted fourth-generation CAR-T cells secreting IL-7 and CCL19 for therapy of refractory\/recurrent multiple myeloma. Front Immunol. 2021;12:609421.","journal-title":"Front Immunol"},{"issue":"1","key":"5125_CR109","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41421-023-00625-0","volume":"10","author":"W Lei","year":"2024","unstructured":"Lei W, et al. Safety and feasibility of anti-CD19 CAR T cells expressing inducible IL-7 and CCL19 in patients with relapsed or refractory large B-cell lymphoma. Cell Discovery. 2024;10(1):5.","journal-title":"Cell Discovery"},{"issue":"10","key":"5125_CR110","doi-asserted-by":"publisher","first-page":"3522","DOI":"10.1016\/j.ymthe.2024.07.020","volume":"32","author":"N Li","year":"2024","unstructured":"Li N, et al. Armored bicistronic CAR T cells with dominant-negative TGF-\u03b2 receptor II to overcome resistance in glioblastoma. Mol Ther. 2024;32(10):3522\u201338.","journal-title":"Mol Ther"},{"issue":"2","key":"5125_CR111","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.cell.2016.09.011","volume":"167","author":"KT Roybal","year":"2016","unstructured":"Roybal KT, et al. Engineering T Cells with Customized Therapeutic Response Programs Using Synthetic Notch Receptors. Cell. 2016;167(2):419\u2013e43216.","journal-title":"Cell"},{"issue":"8","key":"5125_CR112","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1038\/s41375-024-02247-1","volume":"38","author":"IG Walker","year":"2024","unstructured":"Walker IG, et al. Targeting myeloma essential genes using NOT Gated CAR T-cells, a computational approach. Leukemia. 2024;38(8):1848\u201352.","journal-title":"Leukemia"},{"issue":"1","key":"5125_CR113","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s12967-023-04829-6","volume":"22","author":"Y Wang","year":"2024","unstructured":"Wang Y, et al. DNTGF-\u03b2R armored CAR-T cell therapy against tumors from bench to bedside. J Translational Med. 2024;22(1):45.","journal-title":"J Translational Med"},{"issue":"6","key":"5125_CR114","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1182\/bloodadvances.2023011653","volume":"8","author":"D Cancilla","year":"2024","unstructured":"Cancilla D, et al. Targeting CXCR4, VLA-4, and CXCR2 for hematopoietic stem cell mobilization. Blood Adv. 2024;8(6):1379\u201383.","journal-title":"Blood Adv"},{"issue":"Supplement 1","key":"5125_CR115","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1182\/blood-2024-193210","volume":"144","author":"ZD Crees","year":"2024","unstructured":"Crees ZD, et al. Motixafortide (CXCR4 Inhibition) Alone and in Combination with Natalizumab (VLA-4 Inhibition) As a Novel Regimen to Mobilize Hematopoietic Stem Cells for Gene Therapies in Sickle Cell Disease: A First-in-Human, Proof-of-Principle Safety and Feasibility Study. Blood. 2024;144(Supplement 1):145\u2013145.","journal-title":"Blood"},{"issue":"8","key":"5125_CR116","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.3390\/biom14081003","volume":"14","author":"PG Ruminski","year":"2024","unstructured":"Ruminski PG, Rettig MP, DiPersio JF. Development of VLA4 and CXCR4 antagonists for the mobilization of hematopoietic stem and progenitor cells. Biomolecules. 2024;14(8):1003.","journal-title":"Biomolecules"},{"issue":"25","key":"5125_CR117","doi-asserted-by":"publisher","first-page":"7826","DOI":"10.7150\/thno.37216","volume":"9","author":"J Zhuang","year":"2019","unstructured":"Zhuang J, et al. Nanoparticle Delivery of Immunostimulatory Agents for Cancer Immunotherapy. Theranostics. 2019;9(25):7826\u201348.","journal-title":"Theranostics"},{"key":"5125_CR118","doi-asserted-by":"publisher","first-page":"117252","DOI":"10.1016\/j.biopha.2024.117252","volume":"178","author":"H Lin","year":"2024","unstructured":"Lin H, et al. Antigen escape in CAR-T cell therapy: Mechanisms and overcoming strategies. Biomed Pharmacother. 2024;178:117252.","journal-title":"Biomed Pharmacother"},{"issue":"4","key":"5125_CR119","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/NEJMoa2303379","volume":"389","author":"J San-Miguel","year":"2023","unstructured":"San-Miguel J, et al. Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma. N Engl J Med. 2023;389(4):335\u201347.","journal-title":"N Engl J Med"},{"issue":"6","key":"5125_CR120","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","volume":"387","author":"P Moreau","year":"2022","unstructured":"Moreau P, et al. Teclistamab in Relapsed or Refractory Multiple Myeloma. N Engl J Med. 2022;387(6):495\u2013505.","journal-title":"N Engl J Med"},{"issue":"5","key":"5125_CR121","doi-asserted-by":"publisher","first-page":"e205","DOI":"10.1016\/S1470-2045(24)00043-3","volume":"25","author":"P Rodriguez-Otero","year":"2024","unstructured":"Rodriguez-Otero P, et al. International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma. Lancet Oncol. 2024;25(5):e205\u201316.","journal-title":"Lancet Oncol"},{"key":"5125_CR122","doi-asserted-by":"publisher","first-page":"13","DOI":"10.25259\/Cytojournal_64_2023","volume":"21","author":"J Zhang","year":"2024","unstructured":"Zhang J, Ding X, Ding X. Exploring the efficacy and safety of anti-BCMA chimeric antigen receptor T-cell therapy for multiple myeloma: Systematic review and meta-analysis. Cytojournal. 2024;21:13.","journal-title":"Cytojournal"},{"issue":"1","key":"5125_CR123","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1186\/s12967-022-03442-3","volume":"20","author":"T Kouro","year":"2022","unstructured":"Kouro T, Himuro H, Sasada T. Exhaustion of CAR T cells: potential causes and solutions. J Translational Med. 2022;20(1):239.","journal-title":"J Translational Med"},{"issue":"1","key":"5125_CR124","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/s41408-024-01193-6","volume":"14","author":"Z Tao","year":"2024","unstructured":"Tao Z, et al. Impact of T cell characteristics on CAR-T cell therapy in hematological malignancies. Blood Cancer J. 2024;14(1):213.","journal-title":"Blood Cancer J"},{"issue":"15","key":"5125_CR125","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1182\/blood.2024024965","volume":"145","author":"CL Freeman","year":"2025","unstructured":"Freeman CL, et al. Tumor burden quantified by soluble B-cell maturation antigen and metabolic tumor volume determines myeloma CAR-T outcomes. Blood. 2025;145(15):1645\u201357.","journal-title":"Blood"},{"issue":"1","key":"5125_CR126","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1182\/hematology.2023000445","volume":"2023","author":"B Razzo","year":"2023","unstructured":"Razzo B, Garfall AL, Cohen AD. Options at the time of relapse after anti-BCMA therapy. Hematol Am Soc Hematol Educ Program. 2023;2023(1):450\u20138.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"5125_CR127","doi-asserted-by":"publisher","first-page":"1607778","DOI":"10.3389\/fimmu.2025.1607778","volume":"16","author":"L Wei","year":"2025","unstructured":"Wei L, et al. Case Report: Summary of multiple CAR-T expansions in anti-BCMA\/GPRC5D bispecific CAR-T cell therapy for multiple myeloma. Front Immunol. 2025;16:1607778.","journal-title":"Front Immunol"},{"issue":"13","key":"5125_CR128","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.1158\/1078-0432.CCR-15-2224","volume":"22","author":"E Sanchez","year":"2016","unstructured":"Sanchez E, et al. Soluble B-Cell Maturation Antigen Mediates Tumor-Induced Immune Deficiency in Multiple Myeloma. Clin Cancer Res. 2016;22(13):3383\u201397.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"5125_CR129","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s40164-025-00643-6","volume":"14","author":"Y Hu","year":"2025","unstructured":"Hu Y, et al. Mechanisms of resistance to CAR-T cell therapy in multiple myeloma: latest updates from the 2024 ASH annual meeting. Exp Hematol Oncol. 2025;14(1):45.","journal-title":"Exp Hematol Oncol"},{"issue":"6","key":"5125_CR130","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1016\/j.ymthe.2024.04.004","volume":"32","author":"T Ahn","year":"2024","unstructured":"Ahn T, Bae E-A, Seo H. Decoding and overcoming T cell exhaustion: Epigenetic and transcriptional dynamics in CAR-T cells against solid tumors. Mol Ther. 2024;32(6):1617\u201327.","journal-title":"Mol Ther"},{"key":"5125_CR131","doi-asserted-by":"publisher","first-page":"1034257","DOI":"10.3389\/fcell.2022.1034257","volume":"10","author":"X Zhu","year":"2022","unstructured":"Zhu X, Li Q, Zhu X. Mechanisms of CAR T cell exhaustion and current counteraction strategies. Front Cell Dev Biol. 2022;10:1034257.","journal-title":"Front Cell Dev Biol"},{"issue":"26","key":"5125_CR132","doi-asserted-by":"publisher","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","volume":"127","author":"JN Brudno","year":"2016","unstructured":"Brudno JN, Kochenderfer JN. Toxicities of chimeric antigen receptor T cells: recognition and management. Blood. 2016;127(26):3321\u201330.","journal-title":"Blood"},{"issue":"1","key":"5125_CR133","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41598-021-03748-0","volume":"12","author":"D Hathi","year":"2022","unstructured":"Hathi D, et al. Ablation of VLA4 in multiple myeloma cells redirects tumor spread and prolongs survival. Sci Rep. 2022;12(1):30.","journal-title":"Sci Rep"},{"issue":"6","key":"5125_CR134","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/s41408-020-0331-4","volume":"10","author":"P Nair-Gupta","year":"2020","unstructured":"Nair-Gupta P, et al. Blockade of VLA4 sensitizes leukemic and myeloma tumor cells to CD3 redirection in the bone marrow microenvironment. Blood Cancer J. 2020;10(6):65.","journal-title":"Blood Cancer J"},{"key":"5125_CR135","doi-asserted-by":"publisher","first-page":"1381212","DOI":"10.3389\/fimmu.2024.1381212","volume":"15","author":"L Li","year":"2024","unstructured":"Li L, et al. Circulating immune cells and risk of osteosarcoma: a Mendelian randomization analysis. Front Immunol. 2024;15:1381212.","journal-title":"Front Immunol"},{"issue":"23","key":"5125_CR136","doi-asserted-by":"publisher","first-page":"5776","DOI":"10.1016\/j.biomaterials.2012.04.029","volume":"33","author":"MT Stephan","year":"2012","unstructured":"Stephan MT, et al. Synapse-directed delivery of immunomodulators using T-cell-conjugated nanoparticles. Biomaterials. 2012;33(23):5776\u201387.","journal-title":"Biomaterials"},{"issue":"38","key":"5125_CR137","doi-asserted-by":"publisher","first-page":"17699","DOI":"10.1039\/D4NR01780C","volume":"16","author":"K Wells","year":"2024","unstructured":"Wells K, et al. Immunomodulatory nanoparticles activate cytotoxic T cells for enhancement of the effect of cancer immunotherapy. Nanoscale. 2024;16(38):17699\u2013722.","journal-title":"Nanoscale"},{"issue":"26","key":"5125_CR138","doi-asserted-by":"publisher","first-page":"3113","DOI":"10.1182\/blood.2024025655","volume":"145","author":"C Shasha","year":"2025","unstructured":"Shasha C, et al. Hallmarks of T-cell exhaustion and antigen experience are absent in multiple myeloma from diagnosis to maintenance therapy. Blood. 2025;145(26):3113\u201323.","journal-title":"Blood"},{"issue":"6","key":"5125_CR139","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1182\/blood.2023022823","volume":"144","author":"D Cortes-Selva","year":"2024","unstructured":"Cortes-Selva D, et al. Correlation of immune fitness with response to teclistamab in relapsed\/refractory multiple myeloma in the MajesTEC-1 study. Blood. 2024;144(6):615\u201328.","journal-title":"Blood"},{"issue":"4","key":"5125_CR140","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.ccell.2023.02.008","volume":"41","author":"MJ Friedrich","year":"2023","unstructured":"Friedrich MJ, et al. The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients. Cancer Cell. 2023;41(4):711\u201325. .e6.","journal-title":"Cancer Cell"},{"issue":"1","key":"5125_CR141","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s13045-025-01717-y","volume":"18","author":"Q Hu","year":"2025","unstructured":"Hu Q, et al. Extracellular matrix dynamics in tumor immunoregulation: from tumor microenvironment to immunotherapy. J Hematol Oncol. 2025;18(1):65.","journal-title":"J Hematol Oncol"},{"issue":"4","key":"5125_CR142","doi-asserted-by":"publisher","first-page":"e323","DOI":"10.1002\/mco2.323","volume":"4","author":"R Ren","year":"2020","unstructured":"Ren R, et al. The recent progress of myeloid-derived suppressor cell and its targeted therapies in cancers. MedComm. 2023;4(4):e323.","journal-title":"MedComm"},{"key":"5125_CR143","doi-asserted-by":"publisher","first-page":"845422","DOI":"10.3389\/fimmu.2022.845422","volume":"13","author":"A Brevi","year":"2022","unstructured":"Brevi A, et al. The insider: impact of the gut microbiota on cancer immunity and response to therapies in multiple myeloma. Front Immunol. 2022;13:845422.","journal-title":"Front Immunol"},{"issue":"6","key":"5125_CR144","doi-asserted-by":"publisher","first-page":"56","DOI":"10.3390\/hematolrep17060056","volume":"17","author":"MY George","year":"2025","unstructured":"George MY, et al. The gut microbiome role in multiple myeloma: emerging insights and therapeutic opportunities. Hematol Rep. 2025;17(6):56.","journal-title":"Hematol Rep"},{"issue":"4","key":"5125_CR145","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1158\/1078-0432.CCR-23-0195","volume":"30","author":"A Rodr\u00edguez-Garc\u00eda","year":"2024","unstructured":"Rodr\u00edguez-Garc\u00eda A, et al. Short-Chain Fatty Acid Production by Gut Microbiota Predicts Treatment Response in Multiple Myeloma. Clin Cancer Res. 2024;30(4):904\u201317.","journal-title":"Clin Cancer Res"},{"key":"5125_CR146","doi-asserted-by":"publisher","first-page":"1589943","DOI":"10.3389\/fimmu.2025.1589943","volume":"16","author":"S Chen","year":"2025","unstructured":"Chen S, et al. Driving innovations in cancer research through spatial metabolomics: a bibliometric review of trends and hotspot. Front Immunol. 2025;16:1589943.","journal-title":"Front Immunol"},{"issue":"1","key":"5125_CR147","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s13045-025-01722-1","volume":"18","author":"X Cheng","year":"2025","unstructured":"Cheng X, et al. Application of single-cell and spatial omics in deciphering cellular hallmarks of cancer drug response and resistance. J Hematol Oncol. 2025;18(1):70.","journal-title":"J Hematol Oncol"},{"key":"5125_CR148","doi-asserted-by":"crossref","unstructured":"Cook MS, et al. A balanced CAR-T cell metabolism driven by CD28 or 4-1BB co-stimulation correlates with clinical success in lymphoma patients. bioRxiv. 2024. p. 2024.09.27.615167.","DOI":"10.1101\/2024.09.27.615167"},{"issue":"10","key":"5125_CR149","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1038\/s41591-023-02589-w","volume":"29","author":"NJ Bahlis","year":"2023","unstructured":"Bahlis NJ, et al. Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial. Nat Med. 2023;29(10):2570\u20136.","journal-title":"Nat Med"},{"issue":"26","key":"5125_CR150","doi-asserted-by":"publisher","first-page":"3064","DOI":"10.1182\/blood.2025029262","volume":"145","author":"MJ Friedrich","year":"2025","unstructured":"Friedrich MJ, Raab MS. When the silence speaks: T-cell dysfunction in myeloma. Blood. 2025;145(26):3064\u20136.","journal-title":"Blood"},{"issue":"4","key":"5125_CR151","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/mt.2010.24","volume":"18","author":"RA Morgan","year":"2010","unstructured":"Morgan RA, et al. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther. 2010;18(4):843\u201351.","journal-title":"Mol Ther"},{"issue":"3","key":"5125_CR152","doi-asserted-by":"publisher","first-page":"1","DOI":"10.12968\/hmed.2024.0701","volume":"86","author":"J Tao","year":"2025","unstructured":"Tao J, et al. Effect of Bortezomib Treatment in Multiple Myeloma on Blood Coagulation Function, Renal Function, Immune Function, and the NF-\u03baB Pathway-Associated Indicators. Br J Hosp Med (Lond). 2025;86(3):1\u201315.","journal-title":"Br J Hosp Med (Lond)"},{"issue":"5","key":"5125_CR153","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/s41417-024-00750-2","volume":"31","author":"M Sheykhhasan","year":"2024","unstructured":"Sheykhhasan M, et al. CAR T therapies in multiple myeloma: unleashing the future. Cancer Gene Ther. 2024;31(5):667\u201386.","journal-title":"Cancer Gene Ther"},{"key":"5125_CR154","doi-asserted-by":"publisher","first-page":"1413494","DOI":"10.3389\/fonc.2024.1413494","volume":"14","author":"K Lu","year":"2024","unstructured":"Lu K, et al. Advancements in microenvironment-based therapies: transforming the landscape of multiple myeloma treatment. Front Oncol. 2024;14:1413494.","journal-title":"Front Oncol"},{"issue":"8","key":"5125_CR155","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/s41408-022-00716-3","volume":"12","author":"H Chen","year":"2022","unstructured":"Chen H, et al. \u03b3-secretase inhibitors augment efficacy of BCMA-targeting bispecific antibodies against multiple myeloma cells without impairing T-cell activation and differentiation. Blood Cancer J. 2022;12(8):118.","journal-title":"Blood Cancer J"},{"issue":"1","key":"5125_CR156","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/s41408-024-01197-2","volume":"14","author":"M Merz","year":"2024","unstructured":"Merz M, et al. Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy. Blood Cancer J. 2024;14(1):214.","journal-title":"Blood Cancer J"},{"issue":"2","key":"5125_CR157","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1182\/blood.2024025231","volume":"145","author":"DG Coffey","year":"2025","unstructured":"Coffey DG, et al. Single-cell analysis of the multiple myeloma microenvironment after \u03b3-secretase inhibition and CAR T-cell therapy. Blood. 2025;145(2):220\u201333.","journal-title":"Blood"},{"issue":"3","key":"5125_CR158","doi-asserted-by":"publisher","first-page":"e432204","DOI":"10.1200\/EDBK_432204","volume":"44","author":"M Mohan","year":"2024","unstructured":"Mohan M, et al. Charting the Course: Sequencing Immunotherapy for Multiple Myeloma. Am Soc Clin Oncol Educ Book. 2024;44(3):e432204.","journal-title":"Am Soc Clin Oncol Educ Book"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-026-05125-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-05125-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-05125-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T14:03:46Z","timestamp":1781877826000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-026-05125-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,2]]},"references-count":158,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5125"],"URL":"https:\/\/doi.org\/10.1007\/s12672-026-05125-7","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,2]]},"assertion":[{"value":"10 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"925"}}